We believe in Transparency

We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.

COMPLIANCE INSIGHTS

View, monitor and analyze all your compliance data in one place.

HCP ENGAGE

Multichannel solution to better manage consent, disputes and pre-disclosure review.

MARKET VISION

Market and competitor intelligence at your fingertips.

YOUR INSURANCE AGAINST BIG PHARMA SCANDAL

What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?

What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?

Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.

LEARN MORE
Compliance Insights

qorcommunity

The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.

SIGN UP AS AN EXPERT

Seth Whitelaw

Founder of Whitelaw Compliance Group, LLC

Thomas Sullivan

President of Rockpointe

Kristin Buske

Head MSL Excellence at Merck

Elisabeth Kohoutek

Associate at King & Spalding

Maite Vazquez Calo

Legal Expert on Data Privacy

Brian A Dahl

Principal at Dahl Compliance Consulting LLC

Case Study

Efficiency and Foresight: The qordata Advantage For Zimmer Biomet

For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.

DOWNLOAD

Trusted by great companies

Helping thousands of people and companies communicate and work better.

OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.

UPCOMING EVENT

Life Sciences GDPR Bootcamp
14 Nov to 14 Nov, 2017
10:00 am to 6:00 pm BST
Amba Hotel Marble Arch Bryanston Street London, W1H 7EH, UK
VIEW ALL EVENTS

UPCOMING WEBINAR

No Upcoming Webinar
No Upcoming Webinar
No Upcoming Webinar
VIEW ALL WEBINARS

Press Release

qordata Releases Open Payments Data 2016

Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.

READ FULL STORY

Recent Blog Posts

Thought Leadership —Transparency, Insights And Disclosure

Is Consent Rate The Only Measure Of Transparency?—The Big Debate Part II
Zafar Ahmed
Written By Zafar Ahmed

The approach towards data privacy in EU makes consideration towards consent revocation an imperative. If a physician revokes consent, individual versus aggregate spend figures need to be recalculated, and they will show the corresponding changes. Thus, historical consent rate figures may not be an accurate indicator of transparency in that specific market, or even attitude shifts towards transparency. Interest groups that don’t examine consent from this angle tend to make hasty judgments on transparency. The fourth estate is a repeat offender, often citing (or misrepresenting) published data as a way of drawing public attention to “Big Pharma’s Big Money.” Not only does this present a distorted view of pharmaceutical spend activity to the public, but it also discourages relatively open […]

Is Consent Rate The Only Measure Of Transparency?—The Big Debate Part I
Ned Mumtaz
Written By Ned Mumtaz

Physician consent can be a contentious issue. Especially when data privacy interpretation comes into play. In a webinar we hosted, Brian Sharkey, VP of Porzio Life Sciences LLC raised a question about the validity of consent rates as an indicator of pharmaceutical transparency. So, is there a direct correlation between transparency in the pharmaceutical sector and physicians’ attitudes towards consent? Let data give the answers.               How Are You Calculating Physician Consent? As we demonstrated in a webinar last year, the answer to ‘what is physician consent rate?’ can differ substantially depending on how you proceed with the consent calculation process. Some medical drug/device companies will calculate consent based on TOV amount. Hypothetically speaking, […]

How Are Attitudes Shifting Towards Spend Disclosure?
Zafar Ahmed
Written By Zafar Ahmed

How stringent are pharmaceutical disclosure requirements in your country? Depends on who you’re asking. Team qordata invited Brian Sharkey Vice President, Porzio Life Sciences LLC, to host our webinar on “EFPIA Reporting and Consent Management”. What he had to say pretty much confirms that when it comes to compliance disclosure, context is key. Some Measures Go Up, Some Go Down Did anticipated publication match actual publication rates in pharmaceutical spend for 2015 data? Not quite. Switzerland, at 72% was the only country in the EFPIA region where estimated consent equated to actual consent rate. Only three countries, the UK, Italy and Norway experienced the receipt of consent rates which exceeded their estimates; though the difference was marginal (not more than […]

OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.